http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2359465-T3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
filingDate | 2007-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2011-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a5fd08afa0683c122712506440896f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d4ffd2372054edc7de699de2f630d8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8a0f5e9e32b3fb801eec5afc6dfba7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_652f6b904b8c7862caa5c69013ab951a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe952237794d2a730d9ecb0a44d114c3 |
publicationDate | 2011-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | ES-2359465-T3 |
titleOfInvention | OPTIMIZATION OF THE POSITIVE PHILADELPHIA LEUKEMIA TREATMENT WITH THE IMATINIB INHIBITOR OF THE TIROSINA QUINASA ABL. |
abstract | Use of Imatinib or a pharmaceutically acceptable salt thereof for the manufacture of a medicament, for the treatment of a Ph + leukemia, wherein (a) a fixed, predetermined daily amount between 200 and 800 mg of Imatinib mono-mesylate salt is You must administer orally to a human patient suffering from Ph + leukemia, (b) at least one blood sample from that patient, which is collected in the first 3 months of treatment, (c) the minimum plasma level (Cmin ) of Imatinib should be determined, and (d) the dose of Imatinib or a pharmaceutically acceptable salt thereof, should be adjusted in a manner that a Cmin between 1000 and 3000 ng / mL of Imatinib is achieved, when the patient does not reach a Cmin between 1000 and 3000 ng / mL of Imatinib, after administration of the fixed, predetermined amount of Imatinib mono-mesylate salt. |
priorityDate | 2006-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 308.